Bio News
Supernus and Indivior will merge to form a central nervous system (CNS)-focused company with a market capitalization of KRW 11 trillion. The all-stock merger is expected to generate KRW 330 billion in revenue this year. The combined company will retain the Supernus name, complete the transaction within the fourth quarter and focus on four therapeutic areas.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
